Clinical Trials Logo

Clinical Trial Summary

Objectives. Toothpaste contains many potentially harmful ingredients, including some that can lead to serious long-term health problems. Everyday use of oral health care products has increased, highlighting the need for healthcare clinicians and consumers to be informed of the potential benefits and risks associated with these products. The aim of this study is to evaluate possible DNA damages to oral epithelial cells in participants exposed to toothpaste containing fluoride as opposed to the effects of non-fluoride toothpaste.

Materials and Methods. Forty volunteers were selected among students of dental medicine and assigned into two experimental groups. Each group used regular non-fluoride toothpaste for initial two months, followed by the use of fluoride toothpaste of the same brand for the next two months. The buccal epithelial cells were sampled at baseline and 30, 60, 90 and 120 days after the beginning of the research. Chromosomal damages were analyzed by micronucleus assay.


Clinical Trial Description

The study included 40 participants, students of Dental Medicine at the School of Medicine, of the University of Split. There were a total of 12 males and 28 females, aged between 20 and 26 (mean age 23.18 ± 1.48). Subjects were divided into two equal groups, depending on the combination of the toothpaste used.

In the first group, Sensodyne Classic (GlaxoSmithKline, UK) and Sensodyne Fluor (GlaxoSmithKline, UK) were the brands of toothpaste used, while in the second Plidenta 15 Seconds (Neva Ltd., Croatia) and Plidenta Sensitive (Neva Ltd., Croatia) (Table 1). Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation. A detailed medical and dental anamnesis were taken from each participant. In a structured questionnaire, tailored to this study all participants provided answers to questions related to demographic factors (age, gender), personal factors (general health, a medication used, radiation exposure), lifestyle (smoking, alcohol consumption) eating habits and oral hygiene habits. Individuals who smoked three or more cigarettes a day for at least a year were considered as smokers. Those individuals who consumed two or more alcohol units for three or more times a week were not included in the study as well as patients with oral lesions, history of malignancy, and those with removable and fixed prosthodontics, orthodontic appliances. The criterion for selecting participants was to be completely healthy with no systemic disorders and diseases.

Sample collection Samples of buccal epithelial cells were collected from each participant using the swab technique immediately prior to the use of tested toothpaste and 30, 60, 90 and 120 days after the beginning of the research (T0 - control prior to the use of tested toothpaste, T1- 30 days after the beginning of the use of non-fluoride toothpaste, T2 - 60 days after the beginning of the use of non-fluoride toothpaste, T3 - 90 days after the beginning of the study, using fluoride toothpaste for 30 days, T4 - 120 days after the beginning of the study, using fluoride toothpaste for 60 days).

One hour prior the sampling, the participants were asked to abstain from smoking and consuming any food and drinks. After rinsing of the oral cavity for three times with tepid water in order to remove exfoliated cells, a swab was taken by gently brushing the buccal mucosa bilaterally with a cytobrush (Cytobrush Plus, GmbH, Dietramszell-Linden, Germany) and then the samples were applied to coded laboratory glass slides pre-warmed at 37 °C.

Micronucleus assay in buccal epithelial cells The cells applied on microscopic slides were allowed to air-dry and then were fixed in methanol (80% v/v) at 4°C for 20 minutes. Staining was carried out with 5% Giemsa solution for 10 minutes. Afterwards, the slides were rinsed with aqua distillate and air-dried.

The analysis was done under a light microscope Olympus CX40 (Olympus, Tokyo, Japan) with a 400× magnification, and each micronucleus and other nuclear anomalies were additionally verified under 1000× magnification. Two replicate slides were prepared for each subject, and 1000 epithelium cells per preparation were scored for each sampling time.

Statistical analysis Statistical analysis was done by using SPSS software package (IBM Corp., Armonk, NY, USA). By descriptive statistical analysis, the basic statistical parameters (mean, standard error, and standard deviation, and relative standard deviation, median and minimum and maximum values) were determined. The differences in the number of micronuclei and other nuclear anomalies between different sampling times for each group and between the groups of examinees were tested by ANOVA and Tukey's HSD post hoc test using a general linear model procedure. General regression model (GRM) from linear/nonlinear modelling method was used for the assessment of the influence of the predictor variables (age, gender, and profession, use of medication, X-ray exposure, dietary habits, and lifestyle) onto dependent variables (micronucleus, binucleated cells, broken eggs, nuclear buds, pyknosis, condensed chromatin, karyolysis and karyorrhexis). The results of GRM are expressed in the form of Pareto charts of t values. A significance level was set at 0.05. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03325400
Study type Interventional
Source University of Split, School of Medicine
Contact
Status Completed
Phase N/A
Start date January 1, 2016
Completion date July 20, 2016

See also
  Status Clinical Trial Phase
Completed NCT02273713 - The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Phase 1/Phase 2
Terminated NCT00531076 - Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer Phase 1
Active, not recruiting NCT02397434 - Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer N/A
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Active, not recruiting NCT02649491 - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy N/A
Active, not recruiting NCT03975452 - Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer N/A
Terminated NCT00618917 - MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Not yet recruiting NCT02760823 - Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning Phase 2
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT00890448 - Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate N/A
Terminated NCT01760356 - Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
Recruiting NCT06044623 - Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients Phase 3
Completed NCT01091766 - Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine Phase 4
Completed NCT05277480 - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Phase 2
Recruiting NCT03978949 - Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP) Phase 3
Completed NCT03491371 - Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use N/A
Completed NCT02143219 - Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Phase 2
Completed NCT02054741 - Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer N/A
Not yet recruiting NCT06087718 - Feasibility of the Maastro Applicator in Rectal Cancer N/A
Terminated NCT02512809 - Isoflurane-induced Neuroinflammation in Children With Hydrocephalus Phase 3